Robert is Co-Founder and Venture Partner, focusing on healthcare. Robert manages Lux Capital’s investments in Cala Health (neuroperipherals), Kala Pharmaceuticals (ophthalmology), Kyruus (healthcare IT), and Visterra, Inc. (infectious diseases). Previous investments include Cerulean Pharmaceuticals (NASDAQ: CERU – pharmaceutical nanoencapsulation), Magen Biosciences (acquired by PPD – dermatology), and Molecular Imprints (acquired by Canon – semiconductor imprint lithography).
Robert was the founding CEO of Harvard Medical School spinout Genocea Biosciences (NASDAQ: GNCA) and founding CEO of Johns Hopkins spinout Kala Pharmaceuticals (NASDAQ: KALA). Robert was nominated as Biotech CEO of the Year at the World Vaccine Congress and was selected as one of the “100 of the Most Inspiring People” by PharmaVoice Magazine. He was Co-Founder of Lux Research and has served as an advisor to the Bill & Melinda Gates Foundation.
Robert was also a member of Motorola’s Research Visionary Board and has been an invited lecturer or panelist at MIT, Stanford, Yale University, Brown, Memorial Sloan-Kettering Cancer Center, the National Cancer Institute, Georgetown, and the University of Virginia. He has been published in The Journal of Biomedical Materials Research and Nature Biotechnology. Robert graduated from the University of Virginia with a B.S. in Architecture and is a former member of the Regional Selection Committee for UVA’s Jefferson Scholars Foundation.
What is the greatest innovation of the past decade?
Advancements in immune engineering, especially t-cell immunotherapies. Novel infectious disease and autoimmune disorder treatments are on the way thanks to game-changing breakthroughs in our ability to understand how our cellular immune system works.
What are you most looking forward to in the future?
Eradicating alzheimer’s disease and cancer; exponential increases in speed to develop novel vaccines; game-changing scientific breakthroughs in antimicrobial resistance.